Camidanlumab tesirine

ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma

Retrieved on:

Friday, June 10, 2022

Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Other Health, CR, Brentuximab vedotin, Lymphocytopenia, EDT, Company, HSCT, Diffuse large B-cell lymphoma, Biomedical sciences, Genmab, Control, Anemia, Humanitas University, ORR, LinkedIn, Progression-free survival, CEST, Forward-looking statement, Immunogenic cell death, European Hematology Association, Hypophosphatemia, Jaguar XK, BV, Hope, DOR, ADC, U.S. Securities and Exchange Commission, Camidanlumab tesirine, FDA, Hematopoietic stem cell transplantation, Patient, Therapy, Neutropenia, Cancer, PD-1, Technology, NYSE, Lymphatic system, Hodgkin lymphoma, Twitter, MD, Clinical trial, CD25, Department, PBD, Biologics license application, Thrombocytopenia, PFS, GBS, Enzyme, Hematology, Fine chemical, Pharmaceutical industry, San Francisco Bay Area, Camisole

ADC Therapeutics SA (NYSE: ADCT) announced today results from the ongoing pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in relapsed or refractory (r/r) Hodgkin lymphoma.

Key Points:

ADC Therapeutics SA (NYSE: ADCT) announced today results from the ongoing pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in relapsed or refractory (r/r) Hodgkin lymphoma.
Cami has demonstrated consistently favorable response rates and durability in Hodgkin lymphoma patients who have relapsed, despite using the best available treatments.
Cami is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma and a Phase 1b clinical trial as monotherapy and in combination with pembrolizumab in solid tumors.
Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors.

ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress

Retrieved on:

Thursday, May 12, 2022

As we advance Cami toward a potential BLA submission, we look forward to sharing these data with the hematology community at EHA2022.

Key Points:

As we advance Cami toward a potential BLA submission, we look forward to sharing these data with the hematology community at EHA2022.
Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-based payload, killing the cell.
In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million

Retrieved on:

Thursday, August 26, 2021

Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Company, Lymphatic system, CD25, Distortion, Camidanlumab tesirine, Form 6-K, Twitter, Cancer, Immunogenic cell death, Loncastuximab tesirine, Technology, ADC, Jaguar XK, Genmab, Morgan Stanley, Ropes & Gray, Lymphoma, Gibson, Dunn & Crutcher, DNA, Diffuse large B-cell lymphoma, PBD, DNA repair, Food, Therapy, Induced cell cycle arrest, Histology, B-cell lymphoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lymphoid leukemia, Hodgkin lymphoma, NYSE, Achievement, Adult, Patient, Enzyme, LinkedIn, DLBCL, Sale, Genetics, FDA, Control, NOS, Pharmaceutical industry, Fine chemical, Vaccine, ZYNLONTA™ (loncastuximab tesirine-lpyl), Camidanlumab Tesirine (Cami), ADC Therapeutics, HealthCare Royalty, ZYNLONTA™ (LONCASTUXIMAB TESIRINE-LPYL), CAMIDANLUMAB TESIRINE (CAMI), ADC THERAPEUTICS, HEALTHCARE ROYALTY

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced it had entered into a royalty purchase agreement with HealthCare Royalty Partners (HealthCare Royalty).

Key Points:

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced it had entered into a royalty purchase agreement with HealthCare Royalty Partners (HealthCare Royalty).
Upon closing of this transaction, and together with the Companys current cash balance and anticipated business plan, ADC Therapeutics will have a substantial multi-year working capital runway.
HealthCare Royalty purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage life science assets.
HealthCare Royalty has $5.8 billion in cumulative capital commitments with offices in Stamford (CT), San Francisco, Boston and London.

ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma

Retrieved on:

Tuesday, June 22, 2021

The pivotal Phase 2 study is intended to support the submission of a Biologics License Application.

Key Points:

The pivotal Phase 2 study is intended to support the submission of a Biologics License Application.
We also note that the incidence of GBS in Phase 2 is consistent with Phase 1.
We look forward to providing future updates on this pivotal program as the overall response rate and duration of response data continue to mature.
Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors.

ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma

Retrieved on:

Friday, June 18, 2021

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that posters on four ZYNLONTA (loncastuximab tesirine-lpyl) clinical trials were presented at the 16th Annual International Conference on Malignant Lymphoma (ICML).

Key Points:

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that posters on four ZYNLONTA (loncastuximab tesirine-lpyl) clinical trials were presented at the 16th Annual International Conference on Malignant Lymphoma (ICML).
As of the data cut-off date of March 1, 2021, all patients had completed treatment.
ADC Therapeutics CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma

Retrieved on:

Wednesday, June 9, 2021

Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.

Key Points:

Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs).
ADC Therapeutics CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting

Retrieved on:

Friday, June 4, 2021

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced updated clinical data from the ZYNLONTA (loncastuximab tesirine-lpyl) Phase 2 LOTIS-2 trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held virtually June 4-8, 2021.

Key Points:

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced updated clinical data from the ZYNLONTA (loncastuximab tesirine-lpyl) Phase 2 LOTIS-2 trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held virtually June 4-8, 2021.
Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs).
ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology

Retrieved on:

Wednesday, May 26, 2021

The Phase 1 study demonstrates encouraging potential for Cami to provide a new treatment option for patients with relapsed or refractory Hodgkin lymphoma.

Key Points:

The Phase 1 study demonstrates encouraging potential for Cami to provide a new treatment option for patients with relapsed or refractory Hodgkin lymphoma.
Were pleased the results of our Phase 1 trial of Cami in patients with relapsed or refractory lymphoma have been published in The Lancet Haematology, said Jay Feingold, MD, PhD, Senior Vice President and Chief Medical Officer at ADC Therapeutics.
The positive results in patients with Hodgkin lymphoma guided the design of our pivotal Phase 2 trial, which has completed enrollment.
ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting

Retrieved on:

Wednesday, May 19, 2021

Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.

Key Points:

Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms.
Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-based payload killing the cell.
For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn .\nZYNLONTA\xe2\x84\xa2 is a trademark of ADC Therapeutics SA.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210519005976/en/\n'

Biosight Completes Enrollment in Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy

Retrieved on:

Tuesday, May 11, 2021

Cancer treatments, Clinical medicine, Cancer, Acute myeloid leukemia, 7+3, Cytarabine, Tumors of the hematopoietic and lymphoid tissues, Antibody-drug conjugates, Devimistat, Camidanlumab tesirine

Due to its unique pharmacokinetics and metabolism, aspacytarabine enables high-dose therapy with lower systemic exposure to free cytarabine and relative sparing of normal tissues.

Key Points:

Due to its unique pharmacokinetics and metabolism, aspacytarabine enables high-dose therapy with lower systemic exposure to free cytarabine and relative sparing of normal tissues.
For more information regarding the Phase 2b clinical study of BST-236, please visit www.clinicaltrials.gov .\nBiosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders.
Aspacytarabine is currently being investigated as a single agent in\xc2\xa0a Phase 2b for first-line\xc2\xa0treatment of acute myeloid leukemia (AML), following completion of a Phase 1/2a study which demonstrated tolerability with promising efficacy in the challenging population of AML patients unfit for standard of care chemotherapy.
Additional Phase 2 studies in relapsed/refractory AML and MDS, including a study in collaboration with the European cooperative group, GFM.